Fluocortolone

Fluocortolone Overview

Fluocortolone is a synthetic, fluorinated corticosteroid belonging to the potent (Group III) glucocorticoid class. Chemically, it falls under the organic compound class of 21-hydroxysteroids within the steroids and steroid derivatives subclass. Its molecular structure features a fluorine atom at the 6-position and a hydroxyl group at the 21-position of the pregnadiene steroid backbone, which confers enhanced topical anti-inflammatory power and high glucocorticoid receptor selectivity.

In clinical dermatology, endocrinology, and proctology, Fluocortolone is prescribed primarily for the relief of localized skin inflammation, pruritus, and inflammatory dermatoses such as eczema, psoriasis, and dermatitis. It is also formulated as a topical cream or rectal suppository in combination with local anesthetics (e.g., lidocaine) for the symptomatic treatment of hemorrhoids, anal fissures, and proctitis. While it can be administered orally for systemic corticosteroid therapy in select countries, it is most widely used in topical preparations such as Ultralan and Scheriproct.

What Is Fluocortolone and How Does It Work?

Fluocortolone is a small molecule 21-hydroxysteroid that functions as a potent agonist at the human glucocorticoid receptor (GR).

Its primary physiological and intracellular mechanisms include:

• Glucocorticoid Receptor Activation: Fluocortolone diffuses across cell membranes into the cytosol, binding tightly to intracellular glucocorticoid receptors. The drug-receptor complex translocates to the cell nucleus, binding to glucocorticoid response elements (GRE) on DNA to upregulate anti-inflammatory proteins (such as lipocortin-1).
• Inhibition of Inflammatory Mediators: By inducing lipocortin-1, Fluocortolone inhibits phospholipase A2, blocking the release of arachidonic acid and suppressing the synthesis of prostaglandins and leukotrienes.
• Suppression of Cytokines & Transcription Factors: It inhibits key pro-inflammatory transcription factors, including nuclear factor kappa B (NF-kB) and activator protein-1 (AP-1), halting the release of interleukins and tumor necrosis factor-alpha (TNF-alpha).
• Vascular & Antipruritic Actions: Topically applied Fluocortolone reduces capillary permeability, causes localized vasoconstriction, decreases leukocyte infiltration, and dampens sensory nerve sensation to relieve skin redness, swelling, and itching.

Is Fluocortolone FDA Approved?

No, Fluocortolone is not approved by the US FDA for commercial distribution or clinical prescription in the United States. However, it is an established, widely approved Group III potent topical corticosteroid across many international jurisdictions, having been first approved in Europe in 1966 (commonly under brand names like Ultralan and Scheriproct). Internationally, dermatologists and proctologists prescribe Fluocortolone formulations (including fluocortolone pivalate and caproate esters) for the management of eczematous dermatoses, psoriasis, and painful anorectal conditions.

What Is Fluocortolone Used For?

• Symptomatic treatment of inflammatory skin conditions, including eczematous dermatitis, plaque psoriasis, neurodermatitis, and contact allergies.
• Relief of localized pain, itching, and tissue inflammation associated with hemorrhoids, anal fissures, and proctitis (often combined with lidocaine).
• Historical systemic oral corticosteroid therapy for severe autoimmune and inflammatory conditions requiring systemic immunosuppression.

Before Taking Fluocortolone: Contraindications & Precautions

Do not use if you have a documented hypersensitivity or contact allergy to Fluocortolone, fluorinated steroids, or product excipients. Strictly contraindicated in primary viral skin infections (e.g., herpes simplex, varicella), tuberculous or syphilitic skin lesions, perioral dermatitis, rosacea, or untreated bacterial/fungal skin infections lacking appropriate anti-infective coverage. Fluocortolone is not FDA-approved in the United States, though it is widely used internationally. Topical fluorinated corticosteroids carry embryo-fetal toxicity risks; use during pregnancy and lactation only if potential maternal benefits strictly outweigh fetal risks, avoiding large surface areas, prolonged use, or application to the breast area while nursing.

Who Should Not Take Fluocortolone?

• Individuals with a documented hypersensitivity or contact allergy to Fluocortolone, fluorinated steroids, or formulation excipients.
• Patients with primary viral skin infections (such as herpes simplex, varicella, or vaccinia), tuberculous skin lesions, or syphilitic skin manifestations at the treatment site.
• Individuals with rosacea, perioral dermatitis, or fungal/bacterial skin infections lacking appropriate concomitant anti-infective cover.

Fluocortolone, Pregnancy & Fertility

Systemic drug absorption occurs readily across broken skin, mucous membranes, or when used under occlusive dressings. Animal reproduction studies with fluorinated corticosteroids demonstrate embryo-fetal toxicity, intrauterine growth retardation, and teratogenic effects (such as cleft palate). Fluocortolone should be used during pregnancy only if the potential maternal benefit outweighs fetal risk, avoiding large surface areas or prolonged treatment. Caution should be exercised in nursing mothers.

Tell Your Doctor Before Taking Fluocortolone

Inform your dermatologist or physician if you have a history of severe skin atrophy, glaucoma, cataracts, or diabetes mellitus. Disclose any active localized skin infections or recent vaccinations.

Fluocortolone Dosage & Administration

For topical dermatological preparations (0.25% cream or ointment), apply a thin layer to clean, dry, affected skin 1 to 2 times daily, tapering frequency as inflammation improves. For proctological preparations (rectal suppositories or cream, e.g., Scheriproct N), insert 1 suppository rectally 1 to 2 times daily or apply cream to the anorectal area twice daily for a short duration (typically 1 to 2 weeks). Smooth gently onto skin, wash hands thoroughly after application, and avoid applying tight occlusive dressings unless advised by a physician.

Standard Fluocortolone Dosing

• Topical Dermatological Cream / Ointment (0.25%): Apply a thin film to affected skin areas 1 to 2 times daily. As inflammation improves, reduce application to once daily.
• Rectal Suppositories / Proctological Cream (e.g., Scheriproct N): Insert 1 suppository rectally 1 to 2 times daily (or apply cream to the anal region twice daily) for a short duration, typically 1 to 2 weeks.

How Fluocortolone Is Administered

• Administered topically to clean skin or rectally via suppositories.
• Smooth topical creams or ointments gently over the target skin area.
• Wash hands thoroughly after application unless treating the hands.
• Avoid applying tight occlusive dressings over treated skin unless directed by a physician.

Fluocortolone Clinical Efficacy & Research

Clinical trials demonstrate that Fluocortolone 0.25% is a highly effective, potent Group III topical corticosteroid. In double-blind clinical studies evaluating eczematous dermatitis and psoriasis, daily application of Fluocortolone produced rapid reductions in erythema, induration, scaling, and itching compared to baseline. In proctology, combination therapy with lidocaine consistently yields fast pain relief and reduces swollen hemorrhoidal tissue within days of treatment initiation.

Fluocortolone Side Effects & Safety Profile

Common adverse reactions include localized skin burning, stinging, irritation, dryness, scaling, or transient redness at the application site. Serious adverse risks include cutaneous atrophy (skin thinning), telangiectasia, striae, purpura, HPA axis suppression (secondary to systemic absorption from large areas or occlusion), secondary bacterial/fungal superinfections, perioral dermatitis, and acneiform eruptions. Holds no FDA Black Box Warning.

Common Fluocortolone Side Effects

• Localized burning, stinging, or mild skin irritation at the application site.
• Localized skin dryness, scaling, or transient redness.
• Mild rectal stinging or discomfort with suppository insertion.

Serious Fluocortolone Adverse Events

• Cutaneous Atrophy: Thinning of the epidermal and dermal layers, telangiectasia (spider veins), skin striae (stretch marks), and purpura with prolonged use.
• HPA Axis Suppression: Systemic absorption from large skin areas or occlusive dressings can suppress the hypothalamic-pituitary-adrenal axis, inducing Cushingoid features.
• Secondary Infections: Masking or exacerbating underlying bacterial, fungal, or viral skin infections.
• Perioral Dermatitis & Acneiform Eruptions: Specifically when applied inappropriately to facial skin.

Managing Fluocortolone Side Effects

Limit treatment duration on delicate skin areas (such as the face, groin, or flexures) to a maximum of 5 to 7 days. If severe skin irritation, tissue thinning, or secondary infection develops, suspend application immediately and consult a physician.

Fluocortolone Drug Interactions & What to Avoid

Fluocortolone is metabolized by CYP3A4; co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) increases systemic drug exposure if significant dermal absorption occurs, elevating systemic corticosteroid toxicity risks. Do not apply to open wounds or delicate facial/intertriginous skin for extended periods. Systemic food and alcohol interactions are not clinically significant for localized topical or rectal use.

Fluocortolone Drug-Drug Interactions

• CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir): Fluocortolone is metabolized by CYP3A4. Strong inhibitors increase systemic exposure if significant dermal absorption occurs, elevating the risk of systemic corticosteroid side effects.

Fluocortolone, Food & Alcohol

Food and alcohol interactions are not clinically significant for localized topical or rectal formulations.

Fluocortolone: Missed Dose, Overdose & Storage

If a dose is missed, apply or insert it as soon as remembered on that day unless it is almost time for the next scheduled application; do not double up. Acute localized topical or rectal overdose is unlikely to produce systemic toxicity, but chronic overuse across large body surface areas can cause systemic steroid toxicity, fluid retention, hypertension, and HPA axis suppression. Store creams, ointments, and suppositories at controlled room temperature (15°C–25°C) protected from direct light, excessive heat, and freezing.

Missed Dose of Fluocortolone

Apply or insert the missed dose as soon as remembered on that day. If it is close to the next scheduled dose, skip the missed application and resume your regular daily schedule. Do not double doses.

Fluocortolone Overdose & Emergency

Acute overdose via localized topical or rectal application is unlikely to produce systemic toxicity. However, chronic overuse across large surface areas can cause systemic steroid toxicity, fluid retention, blood pressure changes, and HPA axis suppression. In cases of accidental oral ingestion, seek medical advice or contact a poison control center.

How to Store Fluocortolone

Store creams, ointments, and suppositories at controlled room temperature between 15°C and 25°C. Protect from direct heat, excessive moisture, and direct light. Do not freeze. Keep strictly out of reach of children.

Fluocortolone Patient Management & Monitoring

Inspect the target skin site or rectal mucosa prior to starting therapy to rule out untreated viral, fungal, or bacterial infections. Periodically observe treated areas for clinical resolution of dermatitis or anorectal inflammation, and evaluate for early signs of skin thinning, striae, or secondary cutaneous infections. Limit application on delicate areas (face, groin, flexures) to a maximum of 5 to 7 days, and reassess therapy if continuous treatment exceeds 2 to 4 weeks.

Tests Before Starting Fluocortolone

• Visual examination of target skin or rectal mucosa to rule out untreated viral, fungal, or bacterial infections.

Monitoring During Fluocortolone Treatment

Periodically evaluate treated skin for clinical resolution of dermatitis, signs of skin thinning, or secondary cutaneous infection. Monitor for systemic corticosteroid symptoms if applied under occlusion.

Fluocortolone Do’s and Don’ts

• Do apply thinly to clean skin 1 to 2 times daily as directed.
• Do wash hands after applying creams.
• Do not apply to open wounds, face, or groin for extended periods without medical guidance.
• Do not cover treated skin with occlusive bandages unless prescribed.
• Do not use continuously for more than 2 to 4 weeks without reassessment.

Frequently Asked Questions

References

• DrugBank Database – Fluocortolone Clinical and Pharmacological Profile (DB08971)
• Classyfire Database – 21-Hydroxysteroids Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.